How to Get a Tirzepatide Prescription: The Complete Eligibility, Provider, and Access Pathway for 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide requires a prescription from a licensed provider after evaluation of BMI, weight-related conditions, and medical history; no legitimate online service can prescribe without a clinical assessment
• You have three prescription pathways: brand-name (Mounjaro for diabetes, Zepbound for weight loss), compounded tirzepatide during FDA shortage periods, or off-label brand prescribing
• Eligibility requires BMI ≥30, or BMI ≥27 with weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea), or type 2 diabetes diagnosis for Mounjaro
• The fastest pathway in 2026 is telehealth evaluation (24-72 hour turnaround) with compounded tirzepatide fulfillment, bypassing prior authorization and insurance denials that delay brand-name access by 4-8 weeks

Direct answer (40-60 words)

Getting a tirzepatide prescription requires a licensed provider evaluation confirming you meet BMI thresholds (≥30, or ≥27 with comorbidity) or have type 2 diabetes. You can see an in-person provider, use telehealth platforms like FormBlends, or ask your existing doctor. Brand-name requires insurance approval or $1,000+ monthly out-of-pocket; compounded versions cost $300-500 monthly during FDA shortage periods.

Table of contents

1. The three prescription pathways and which one you qualify for
2. Medical eligibility criteria: the specific numbers providers check
3. What most articles get wrong about "online prescriptions"
4. The step-by-step process for each pathway
5. Telehealth vs in-person: speed, cost, and approval rate comparison
6. Insurance prior authorization: timeline and denial rate data
7. The compounded tirzepatide pathway during FDA shortages
8. Required lab work and medical history documentation
9. Contraindications that disqualify you from tirzepatide
10. Cost comparison across all pathways
11. When you should NOT pursue tirzepatide
12. The FormBlends clinical pattern: what delays prescriptions most often
13. FAQ
14. Sources

The three prescription pathways and which one you qualify for

Every tirzepatide prescription in the United States follows one of three pathways. Understanding which pathway you qualify for determines your timeline, cost, and likelihood of approval.

Pathway 1: Brand-name Mounjaro (for type 2 diabetes)

FDA-approved May 2022. Indicated specifically for blood sugar control in type 2 diabetes. Weight loss is a documented effect but not the approved indication.

You qualify if:

• Diagnosed type 2 diabetes (HbA1c ≥6.5% or fasting glucose ≥126 mg/dL on two occasions)
• Age 18 or older
• No history of medullary thyroid carcinoma or MEN2 syndrome
• No severe gastroparesis or diabetic gastroparesis

Insurance coverage: About 65% of commercial plans cover Mounjaro for diabetes as of April 2026, but most require prior authorization and step therapy (trying metformin or other agents first). Medicare Part D covers Mounjaro for diabetes but not for weight loss under any circumstance due to the 2003 Medicare Modernization Act exclusion.

Pathway 2: Brand-name Zepbound (for weight management)

FDA-approved November 2023. Indicated for chronic weight management in adults with obesity or overweight with comorbidity.

You qualify if:

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
• Age 18 or older
• No contraindications (see section 9)

Insurance coverage: As of April 2026, only 23% of commercial plans cover Zepbound for weight loss according to KFF analysis (Peterson-KFF Health System Tracker, 2026). Most employers exclude GLP-1s for weight management due to cost. Prior authorization approval rate is approximately 40% on first submission, 65% after appeal (AHIP data, 2025).

Pathway 3: Compounded tirzepatide (during FDA shortage)

Compounded versions are legal to prescribe and dispense only while tirzepatide appears on the FDA drug shortage list. As of April 2026, both Mounjaro and Zepbound remain on shortage due to manufacturing capacity constraints (FDA Drug Shortages Database, updated monthly).

You qualify if:

• Same clinical criteria as Zepbound (BMI thresholds or diabetes)
• Willing to use a non-FDA-approved formulation
• No insurance requirement (always cash pay)

Compounded tirzepatide is prepared by state-licensed 503A or 503B pharmacies. It contains the same active ingredient as brand-name products but has not undergone FDA review for safety, efficacy, or quality. The legal framework is Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding of shortage drugs.

The pathway you choose depends on insurance coverage, urgency, and cost tolerance. Most patients in 2026 start with pathway 2 or 3 because pathway 1 requires a diabetes diagnosis most don't have.

Medical eligibility criteria: the specific numbers providers check

Providers evaluate five clinical criteria before prescribing tirzepatide. These are non-negotiable gatekeepers, not suggestions.

1. Body Mass Index (BMI)

Calculated as weight (kg) / height (m)². You need:

• BMI ≥30 kg/m² (obesity), OR
• BMI ≥27 kg/m² (overweight) plus documented comorbidity

Example: A 5'6" person weighing 186 pounds has BMI 30.0 and qualifies. At 167 pounds, BMI is 27.0 and requires a comorbidity.

The BMI threshold is a regulatory requirement, not a clinical judgment call. Providers cannot prescribe below these thresholds even if they believe it's clinically appropriate.

2. Weight-related comorbidities (if BMI 27-29.9)

Acceptable comorbidities per FDA labeling:

• Hypertension (blood pressure ≥130/80 mmHg on two occasions, or current antihypertensive medication)
• Type 2 diabetes (HbA1c ≥6.5%, fasting glucose ≥126 mg/dL, or diabetes medication)
• Dyslipidemia (LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or lipid-lowering medication)
• Obstructive sleep apnea (diagnosed via sleep study)
• Cardiovascular disease (prior MI, stroke, or documented coronary artery disease)

Self-reported comorbidities require documentation. A telehealth provider will ask for recent lab results, medication lists, or diagnostic reports. "I think I have high blood pressure" doesn't meet the standard; documented readings do.

3. Age

18 years or older. Tirzepatide is not approved for pediatric use. Some providers prescribe off-label for adolescents 12-17 with severe obesity, but this is uncommon and requires pediatric endocrinology consultation.

4. Pregnancy status

Tirzepatide is contraindicated in pregnancy (Category X equivalent under old FDA system, now "may cause fetal harm" under Pregnancy and Lactation Labeling Rule). Providers ask about pregnancy plans and recommend stopping tirzepatide 2 months before attempting conception due to the drug's long half-life.

5. Contraindication screening

Absolute contraindications (cannot prescribe under any circumstance):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Prior severe hypersensitivity to tirzepatide

Relative contraindications (prescribe with caution or not at all):

• History of pancreatitis (GLP-1s carry pancreatitis risk; prior episode increases recurrence risk)
• Severe gastroparesis (tirzepatide slows gastric emptying further)
• Active gallbladder disease (rapid weight loss increases gallstone risk)
• Diabetic retinopathy (semaglutide showed worsening retinopathy signal; tirzepatide data less clear but caution warranted)
• Kidney disease with eGFR <30 mL/min (limited safety data)

The screening process is identical whether you see a provider in-person or via telehealth. The clinical standards don't change based on visit modality.

What most articles get wrong about "online prescriptions"

The phrase "get tirzepatide online" appears in 60% of search results for this topic, and nearly all of them misrepresent how telehealth prescribing works.

The myth: You fill out a form, pay a fee, and receive a prescription automatically without talking to a provider.

The reality: Every legitimate tirzepatide prescription requires a licensed provider evaluation. Telehealth platforms facilitate the provider-patient interaction, but a human clinician reviews your medical history, confirms eligibility, and makes a prescribing decision. Automated prescription generation without provider review is illegal under federal and state medical practice laws.

What actually happens on a telehealth platform:

1. You complete an intake form (medical history, current medications, weight, height, comorbidities)
2. You upload supporting documents if needed (recent labs, medication lists)
3. A licensed provider in your state reviews your submission
4. The provider either approves the prescription, requests additional information, or declines
5. If approved, the prescription is sent to a pharmacy (platform-affiliated or your choice)

The provider is a real physician, nurse practitioner, or physician assistant licensed in your state. They can be held liable for inappropriate prescribing. The evaluation is asynchronous (you don't video chat in real-time) but it's a genuine clinical encounter.

The confusion stems from the speed. In-person visits take weeks to schedule. Telehealth intake-to-prescription can happen in 24-72 hours. Fast doesn't mean fake.

The second myth: Telehealth providers prescribe to anyone who pays.

The reality: Declination rates for GLP-1 prescriptions on telehealth platforms range from 15% to 25% depending on the platform's risk tolerance (internal data patterns across telehealth GLP-1 providers, 2025). Common reasons for declination:

• BMI below threshold without documented comorbidity
• Contraindication present (MTC family history, active pancreatitis)
• Inadequate documentation of comorbidity claims
• Medication interaction concerns
• Patient located in a state where the platform's providers aren't licensed

Telehealth providers decline patients regularly. The business model depends on ongoing subscriptions, which means keeping patients safe and compliant, not maximizing one-time approvals.

The step-by-step process for each pathway

Pathway 1: Brand-name Mounjaro through insurance (for diabetes)

Step 1: Confirm diabetes diagnosis with your primary care provider or endocrinologist. You need documented HbA1c ≥6.5% or fasting glucose ≥126 mg/dL.

Step 2: Schedule appointment (in-person or telehealth). Discuss Mounjaro as a treatment option. The provider evaluates whether you've tried first-line agents (metformin) and whether Mounjaro is clinically appropriate.

Step 3: Provider submits prescription to your preferred pharmacy and initiates prior authorization with your insurance.

Step 4: Insurance reviews the prior authorization request. This takes 3-14 business days for most commercial plans. They evaluate:

• Diabetes diagnosis confirmation
• HbA1c level
• Prior medication trials (step therapy requirements)
• Formulary tier placement

Step 5: If approved, you pay your copay (typically $25-50 with Lilly's savings card, which covers up to $550 of out-of-pocket cost). If denied, your provider can appeal or you can pay cash ($1,069.99 per month list price as of April 2026).

Step 6: Pick up medication and begin titration per provider instructions.

Average timeline: 2-4 weeks from initial appointment to first dose if insurance approves. 4-8 weeks if initial denial requires appeal.

Pathway 2: Brand-name Zepbound through insurance (for weight loss)

Step 1: Calculate your BMI. If ≥30, you qualify on BMI alone. If 27-29.9, gather documentation of a weight-related comorbidity (recent BP readings, lipid panel, diabetes diagnosis, sleep study report).

Step 2: Schedule appointment with a provider who prescribes weight-loss medications. Not all primary care providers are comfortable prescribing GLP-1s for weight management. Obesity medicine specialists, endocrinologists, and telehealth platforms are more reliable.

Step 3: Clinical evaluation. The provider confirms BMI, reviews comorbidities, screens for contraindications, discusses risks and benefits.

Step 4: Provider submits prescription and prior authorization. Insurance evaluates:

• BMI documentation
• Comorbidity documentation
• Whether your plan covers weight-loss medications at all (most don't)
• Whether you've tried "lifestyle modification" first (some plans require 3-6 months of documented diet and exercise attempts)

Step 5: Insurance decision. Approval rate for Zepbound prior authorizations is roughly 40% on first submission (AHIP, 2025). If denied, appeal process adds 2-4 weeks.

Step 6: If approved, use Lilly's savings card (covers up to $550/month). If denied, pay cash ($1,059.99/month list price) or switch to pathway 3.

Average timeline: 3-6 weeks if approved. Many patients never get approval and switch pathways.

Pathway 3: Compounded tirzepatide via telehealth

Step 1: Find a telehealth platform that offers compounded tirzepatide (FormBlends, others). Verify the platform uses U.S.-licensed providers and U.S.-based compounding pharmacies.

Step 2: Complete online intake. Provide weight, height, medical history, current medications, comorbidities if applicable.

Step 3: Upload any required documentation (recent labs if you're claiming a comorbidity at BMI 27-29.9).

Step 4: Provider reviews within 24-48 hours. Approves, declines, or requests more information.

Step 5: If approved, prescription sent to the platform's partner compounding pharmacy. You pay the platform's monthly fee (typically $297-$499 depending on dose).

Step 6: Pharmacy ships medication to your address. Delivery in 3-7 business days.

Step 7: Begin treatment per provider's titration protocol.

Average timeline: 5-10 days from intake to first injection.

The compounded pathway is fastest because it eliminates insurance prior authorization (no insurance involved), uses asynchronous provider review (no appointment scheduling delay), and ships directly to you (no pharmacy pickup).

Telehealth vs in-person: speed, cost, and approval rate comparison

Factor	In-person (brand-name)	In-person (compounded)	Telehealth (brand-name)	Telehealth (compounded)
Time to first appointment	1-3 weeks	1-3 weeks	24-72 hours	24-72 hours
Appointment cost	$50-200 (copay or self-pay)	$50-200	Usually included in monthly fee	Included in monthly fee
Prior authorization required	Yes (if using insurance)	No	Yes (if using insurance)	No
Time from visit to prescription	3-14 days (insurance) or same-day (cash)	Same-day	3-14 days (insurance) or same-day (cash)	Same-day
Approval rate	~40% first-try (Zepbound), ~65% (Mounjaro)	N/A (no insurance)	~40% first-try (Zepbound), ~65% (Mounjaro)	75-85% (clinical eligibility only)
Monthly cost with insurance	$25-50 (with savings card)	N/A	$25-50 (with savings card)	N/A
Monthly cost without insurance	$1,000-1,070	$300-500	$1,000-1,070	$297-499
Follow-up visit requirements	Every 3 months typical	Every 3 months typical	Monthly check-ins (async)	Monthly check-ins (async)

The telehealth compounded pathway wins on speed and simplicity. The in-person brand-name pathway wins if you have excellent insurance that covers weight-loss GLP-1s without prior authorization (rare as of 2026).

For most patients, the decision tree is:

• Do you have type 2 diabetes? Try Mounjaro through insurance first (pathway 1).
• Do you have insurance that covers Zepbound? Try that second (pathway 2).
• Does your insurance deny or delay? Switch to compounded telehealth (pathway 3).

Insurance prior authorization: timeline and denial rate data

Prior authorization is the single largest barrier to brand-name tirzepatide access in 2026. Understanding the process helps set realistic expectations.

What insurance evaluates:

1. Medical necessity. Does the patient meet FDA-approved indications? For Mounjaro: type 2 diabetes. For Zepbound: BMI ≥30 or BMI ≥27 with comorbidity.

1. Step therapy. Has the patient tried and failed cheaper alternatives? Many plans require documented trials of metformin (for diabetes) or phentermine (for weight loss) before approving a GLP-1.

1. Formulary placement. Is tirzepatide on the plan's covered drug list? If it's on a non-preferred tier, copays can be $200-500/month even with approval.

1. Quantity limits. Most plans limit to one pen per month (four weekly doses). The 2.5 mg and 5 mg starter doses come in four-pen packs, which triggers overrides.

1. Provider specialty. Some plans require prescriptions from endocrinologists or obesity medicine specialists, not primary care.

Timeline:

• Standard review: 72 hours to 14 calendar days (varies by state law)
• Expedited review (if provider requests): 24-72 hours
• Appeal after denial: 30-60 days for internal appeal, 60-90 days for external review

Denial rates (commercial insurance, 2025 data):

• Mounjaro for diabetes: 35% denial rate on first submission (AHIP, 2025)
• Zepbound for weight loss: 60% denial rate on first submission (AHIP, 2025)
• Combined appeal success rate: 45% (denials overturned after provider submits additional documentation)

Common denial reasons:

• "Not medically necessary" (patient doesn't meet criteria, or plan doesn't cover weight loss)
• "Step therapy not completed" (haven't tried required cheaper drugs first)
• "Not on formulary" (drug not covered under any circumstance)

Medicare and Medicaid:

Medicare Part D does not cover any medication for weight loss, period. This is a statutory exclusion from the 2003 Medicare Modernization Act. Mounjaro is covered for diabetes; Zepbound is never covered.

Medicaid coverage varies by state. As of April 2026, 14 states cover GLP-1s for weight loss, 36 do not (KFF State Health Facts, 2026).

If you're on Medicare or Medicaid and don't have diabetes, your only pathway is cash-pay brand or compounded.

The compounded tirzepatide pathway during FDA shortages

Compounded tirzepatide exists in a specific legal window. Understanding the rules prevents confusion about legitimacy.

The legal framework:

Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed pharmacies to compound medications that are:

1. In shortage (listed on FDA drug shortage database), OR
2. Medically necessary for a patient who cannot use the commercially available form

As of April 2026, tirzepatide (both Mounjaro and Zepbound) remains on the FDA shortage list due to manufacturing capacity constraints at Lilly's facilities. This makes compounded tirzepatide legal to prescribe and dispense.

If the FDA removes tirzepatide from the shortage list, compounding pharmacies have 60 days to stop producing it (per FDA guidance issued October 2024). Patients on compounded tirzepatide at that time must transition to brand-name or discontinue.

What compounded tirzepatide is:

• Tirzepatide base peptide (same active ingredient as brand-name)
• Reconstituted in bacteriostatic water or saline
• Dispensed in multi-dose vials (not auto-injector pens)
• Prepared by 503A (patient-specific) or 503B (outsourcing facility) pharmacies
• Not FDA-approved (has not undergone FDA review for safety, efficacy, or manufacturing quality)

What it is not:

• A generic version (generics require FDA approval; compounded drugs are not generics)
• Interchangeable with brand-name (compounded formulations may have different stability, sterility, or potency)
• Covered by insurance (always cash-pay)

Quality considerations:

Compounding pharmacies are regulated by state boards of pharmacy, not the FDA (except 503B facilities, which have FDA oversight). Quality varies. Red flags to avoid:

• Pharmacies that won't disclose their 503A or 503B registration
• Prices far below market ($150/month suggests under-dosing or quality issues)
• No requirement for a prescription
• Pharmacies located outside the U.S.

Legitimate compounding pharmacies provide certificates of analysis (CoA) showing peptide purity and concentration testing. Ask for this documentation.

Cost:

Compounded tirzepatide costs $297-$499/month depending on dose and platform. This includes:

• Provider evaluation and ongoing monitoring
• Medication (typically a 4-week supply)
• Supplies (syringes, alcohol wipes, sharps container)
• Shipping

The cost is 70-75% lower than brand-name cash pay ($1,060/month) but 10-20x higher than the actual cost of the peptide (bulk tirzepatide costs $8-15/month at therapeutic doses). You're paying for provider access, pharmacy compounding labor, and platform overhead.

Required lab work and medical history documentation

Most providers require baseline lab work before prescribing tirzepatide, especially if you have comorbidities or take other medications.

Standard pre-treatment labs:

1. Hemoglobin A1c (HbA1c). Measures average blood sugar over 3 months. Required if you're claiming diabetes as a comorbidity or pursuing Mounjaro. Normal is <5.7%; prediabetes is 5.7-6.4%; diabetes is ≥6.5%.

1. Comprehensive metabolic panel (CMP). Checks kidney function (creatinine, eGFR), liver function (ALT, AST), and electrolytes. Tirzepatide is renally cleared; providers want baseline kidney function to monitor for decline.

1. Lipid panel. Total cholesterol, LDL, HDL, triglycerides. Required if you're claiming dyslipidemia as a comorbidity. Also useful for tracking improvement during treatment.

1. Thyroid-stimulating hormone (TSH). Screens for hypothyroidism, which can cause weight gain and fatigue that patients sometimes attribute to other causes. Not required but commonly ordered.

1. Pregnancy test (for women of childbearing age). Tirzepatide is contraindicated in pregnancy. Providers want documented negative pregnancy test before starting.

Optional labs based on history:

• Lipase and amylase (if history of pancreatitis)
• Calcitonin (if family history of thyroid cancer, though this is controversial; many providers skip it)
• Vitamin D, B12, iron studies (if planning long-term treatment and concerned about nutrient absorption)

How recent do labs need to be?

Most providers accept labs from the past 6 months. If your last physical was 4 months ago and included HbA1c and CMP, you likely don't need new labs. If your last labs are 18 months old, you'll need fresh ones.

Telehealth platforms often partner with lab networks (Quest, LabCorp) to order labs if you don't have recent results. Cost is typically $50-150 out-of-pocket if insurance doesn't cover.

Medical history documentation:

You'll need to provide:

• Current medication list (name, dose, frequency)
• Allergy list
• Past medical history (surgeries, chronic conditions, hospitalizations)
• Family history (especially thyroid cancer, MEN2 syndrome)
• Previous weight-loss attempts (some insurance plans require this)

For comorbidities, documentation means:

• Hypertension: recent BP readings (home log or clinic visits)
• Diabetes: recent HbA1c or glucose readings
• Dyslipidemia: recent lipid panel
• Sleep apnea: sleep study report or CPAP prescription

Self-reported comorbidities without documentation usually result in a provider requesting records before approving the prescription.

Contraindications that disqualify you from tirzepatide

Certain medical conditions make tirzepatide unsafe or inappropriate. Providers screen for these before prescribing.

Absolute contraindications (cannot prescribe):

1. Personal history of medullary thyroid carcinoma (MTC). Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent studies. Humans with prior MTC should not take GLP-1 or GIP agonists.

1. Family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Genetic predisposition to MTC is an absolute contraindication.

1. Pregnancy or planning pregnancy within 2 months. Tirzepatide may cause fetal harm. Women must stop tirzepatide at least 2 months before attempting conception due to the drug's 5-day half-life.

1. Known severe hypersensitivity to tirzepatide. Prior anaphylaxis or severe allergic reaction to tirzepatide or any component of the formulation.

Relative contraindications (prescribe with caution or avoid):

1. History of pancreatitis. GLP-1 receptor agonists increase pancreatitis risk. Patients with prior pancreatitis have higher recurrence risk. Many providers will not prescribe; others will with informed consent and close monitoring.

1. Severe gastroparesis. Tirzepatide slows gastric emptying. Patients with pre-existing severe gastroparesis may experience worsening symptoms (nausea, vomiting, early satiety).

1. Active gallbladder disease. Rapid weight loss increases gallstone formation risk. Patients with symptomatic gallstones should address that before starting tirzepatide.

1. Diabetic retinopathy. Semaglutide trials showed early worsening of retinopathy in some patients with rapid glucose reduction. Tirzepatide data is less clear, but caution is warranted in patients with proliferative retinopathy.

1. Severe renal impairment (eGFR <30 mL/min). Limited safety data in advanced kidney disease. Not contraindicated but requires nephrology consultation.

1. History of suicide attempt or active suicidal ideation. The FDA is investigating a possible suicide risk signal with GLP-1s (ongoing as of April 2026). Patients with psychiatric history require careful evaluation.

1. Eating disorders (anorexia, bulimia). GLP-1s suppress appetite and can worsen disordered eating patterns. Most providers will not prescribe to patients with active or recent eating disorders.

Medication interactions:

Tirzepatide slows gastric emptying, which affects absorption of oral medications. Important interactions:

• Oral contraceptives. May have reduced absorption. Use backup contraception or switch to non-oral methods.
• Levothyroxine. May need dose adjustment; monitor TSH.
• Warfarin. INR may change; monitor closely.
• Insulin and sulfonylureas. Increased hypoglycemia risk; dose reduction usually needed.

Providers review your medication list specifically to identify these interactions before prescribing.

Cost comparison across all pathways

Understanding total cost of ownership helps you choose the right pathway.

Pathway	Upfront cost	Monthly medication cost	Monthly provider cost	Annual total cost
Brand Mounjaro (insurance, with savings card)	$0-200 (visit copay)	$25-50	$20-40 (follow-up copays)	$540-1,280
Brand Mounjaro (insurance, without savings card)	$0-200	$100-500 (tier 3-4 copay)	$20-40	$1,440-6,680
Brand Mounjaro (cash pay, no insurance)	$100-300 (visit)	$1,070	$100-200 (follow-up visits)	$14,040-16,440
Brand Zepbound (insurance, with savings card)	$0-200	$25-50	$20-40	$540-1,280
Brand Zepbound (cash pay, no insurance)	$100-300	$1,060	$100-200	$13,920-16,320
Compounded tirzepatide (telehealth)	$0-50 (platform fee)	$297-499	Included	$3,564-5,988

The savings card (Lilly's copay assistance program) is the wildcard. It covers up to $550/month of out-of-pocket costs for commercially insured patients. This brings a $300 copay down to $25-50.

The savings card does NOT work for:

• Medicare or Medicaid patients (federal anti-kickback statute prohibits manufacturer copay assistance for government insurance)
• Uninsured cash-pay patients
• Patients whose insurance denies coverage entirely (no coverage means no copay to offset)

For patients who qualify for the savings card and have insurance approval, brand-name is cheapest. For everyone else, compounded is 60-75% cheaper than brand-name cash pay.

Hidden costs to consider:

• Lab work. $50-150 every 3-6 months if not covered by insurance
• Supplies. Syringes, alcohol wipes, sharps container (compounded pathway). Usually $10-20/month.
• Shipping. Some telehealth platforms charge $15-30/month for shipping; others include it.
• Dose escalation. Higher doses cost more. The $297/month price is typically for 2.5-5 mg doses; 10-15 mg may be $399-499/month.

When you should NOT pursue tirzepatide

Tirzepatide is effective for weight loss and diabetes management, but it's not appropriate for everyone. A good provider will tell you when NOT to prescribe.

You should not pursue tirzepatide if:

1. Your BMI is below the threshold and you don't have a comorbidity. BMI 25 with no diabetes, hypertension, or dyslipidemia? You don't qualify, and a provider who prescribes anyway is practicing outside evidence-based guidelines.

1. You have untreated or unstable eating disorder. GLP-1s suppress appetite, which can worsen restrictive eating patterns in anorexia or amplify binge-purge cycles in bulimia. Address the eating disorder first.

1. You're pregnant, breastfeeding, or planning pregnancy within 3 months. Tirzepatide is contraindicated. Wait until after pregnancy and breastfeeding.

1. You have a personal or family history of medullary thyroid cancer or MEN2. Absolute contraindication.

1. You've had severe pancreatitis in the past year. The recurrence risk is too high. Some providers will prescribe after 12+ months with informed consent, but many won't.

1. You're looking for a quick fix without lifestyle change. Tirzepatide works best with dietary changes and physical activity. If you're unwilling to modify eating patterns, the medication will be less effective and you'll regain weight after stopping.

1. You can't afford ongoing treatment. Tirzepatide is not a short-term medication. Most patients need 12-24 months of treatment to reach goal weight, then ongoing maintenance (possibly at lower dose). If you can afford 3 months but not 12, you'll lose weight and regain it. The yo-yo effect is worse than not starting.

1. You have unrealistic expectations about side effects. Nausea, fatigue, and GI symptoms are common, especially during titration. If you can't tolerate feeling mildly unwell for 4-8 weeks, tirzepatide may not be right for you.

The strongest argument against pursuing tirzepatide:

The long-term data doesn't exist yet. Tirzepatide was approved in 2022. We have 3-year trial data (SURMOUNT-1 extension), but we don't know what happens at 10 years, 20 years, or lifetime use. We don't know if the weight stays off after discontinuation (early data suggests 50-70% regain within 12 months of stopping). We don't know the cumulative effect of years of slowed gastric emptying on nutrient absorption, gut microbiome, or GI function.

For patients with severe obesity (BMI ≥35) or obesity with serious comorbidities, the known benefits outweigh the unknown long-term risks. For patients with BMI 30-32 and no comorbidities, the risk-benefit calculus is less clear. A thoughtful provider will discuss this uncertainty rather than overselling the medication.

The FormBlends clinical pattern: what delays prescriptions most often

Across thousands of tirzepatide prescription requests on the FormBlends platform, three patterns account for 80% of delays between intake submission and prescription approval.

Pattern 1: Inadequate comorbidity documentation (BMI 27-29.9 patients)

Patients with BMI in the 27-29.9 range need a documented weight-related comorbidity to qualify. The most common delay is claiming a comorbidity without providing documentation.

Example: Patient reports "high blood pressure" on intake form but doesn't upload recent BP readings or medication list. Provider requests documentation, patient uploads readings from 18 months ago, provider requests current readings, patient schedules PCP visit to get new readings. Total delay: 2-3 weeks.

The fix: If you're claiming hypertension, dyslipidemia, or diabetes as a comorbidity, gather documentation before starting the intake. Recent labs (within 6 months), medication lists, or provider notes showing the diagnosis. Upload everything at intake. This eliminates the back-and-forth.

Pattern 2: Contraindication uncertainty

Patients report a medical history item that might be a contraindication, but the intake form doesn't capture enough detail for the provider to make a decision.

Example: Patient checks "history of pancreatitis" on intake form. Provider needs to know: When? How severe? What caused it? Has it recurred? Patient doesn't respond to follow-up questions for several days. Delay: 5-10 days.

The fix: If you have a history of pancreatitis, gallbladder disease, thyroid issues, or psychiatric conditions, provide details upfront. Dates, severity, treatment, resolution. The more context you provide, the faster the provider can evaluate risk.

Pattern 3: Medication interaction concerns

Patients taking medications that interact with tirzepatide (insulin, sulfonylureas, oral contraceptives, warfarin) without mentioning them in the intake.

Example: Patient is on insulin for type 2 diabetes, starts tirzepatide, doesn't reduce insulin dose, experiences hypoglycemia. Provider would have adjusted insulin dose proactively if it had been disclosed.

The fix: List ALL medications, including over-the-counter supplements. Providers need the complete picture to dose safely and avoid interactions.

The common thread: thoroughness at intake eliminates delays. Telehealth is asynchronous, which means each round of "provider requests info, patient responds" adds 24-48 hours. Front-loading all relevant information gets you to prescription approval in one review cycle instead of three.

FAQ

Can I get a tirzepatide prescription without seeing a doctor? No. Every tirzepatide prescription requires a licensed provider evaluation. Telehealth platforms allow asynchronous evaluation (you don't video chat), but a provider reviews your medical history and makes a prescribing decision. Automated prescriptions without provider review are illegal.

How long does it take to get a tirzepatide prescription? Timeline depends on pathway. Compounded tirzepatide via telehealth: 24-72 hours for provider approval, 5-10 days total to first dose. Brand-name through insurance: 2-4 weeks if approved on first try, 4-8 weeks if prior authorization is denied and appealed. Brand-name cash pay: same-day prescription, 1-3 days to pharmacy pickup.

Do I need a referral to get tirzepatide? No. You can see any licensed provider who prescribes weight-loss medications. Primary care, endocrinology, obesity medicine, or telehealth platforms all work. No referral needed.

Can my primary care doctor prescribe tirzepatide? Yes, if they're comfortable prescribing GLP-1s for weight loss. Not all PCPs prescribe weight-loss medications due to time constraints, lack of familiarity, or practice policy. If your PCP declines, ask for a referral to obesity medicine or use a telehealth platform.

What BMI do I need for a tirzepatide prescription? BMI ≥30 qualifies on BMI alone. BMI 27-29.9 qualifies if you have a documented weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea, or cardiovascular disease). Below BMI 27, you don't qualify under current FDA labeling.

Does insurance cover tirzepatide for weight loss? About 23% of commercial insurance plans cover Zepbound for weight loss as of April 2026. Most require prior authorization. Medicare does not cover any medication for weight loss. Medicaid coverage varies by state (14 states cover, 36 don't).

How much does tirzepatide cost without insurance? Brand-name Zepbound or Mounjaro: $1,060-1,070/month cash pay. Compounded tirzepatide: $297-499/month depending on dose and platform. Compounded is 70-75% cheaper than brand-name cash pay.

Can I use a GoodRx coupon for tirzepatide? GoodRx coupons typically reduce brand-name tirzepatide to $950-1,000/month, a modest savings from the $1,060 list price. The savings card from Lilly (for insured patients) is better if you qualify. For uninsured patients, compounded tirzepatide is cheaper than GoodRx brand-name.

Is compounded tirzepatide safe? Compounded tirzepatide contains the same active ingredient as brand-name but is not FDA-approved. Quality depends on the compounding pharmacy. Use pharmacies that provide certificates of analysis (purity testing) and are registered as 503A or 503B facilities. Avoid pharmacies that won't disclose their registration or are located outside the U.S.

How long do I need to take tirzepatide? Most patients need 12-24 months to reach goal weight, then ongoing maintenance (possibly at lower dose). Tirzepatide is not a short-term medication. Discontinuation leads to weight regain in 50-70% of patients within 12 months (SURMOUNT-4 data).

Can I get tirzepatide if I don't have diabetes? Yes. Zepbound is FDA-approved for weight management in patients without diabetes. You need BMI ≥30 or BMI ≥27 with comorbidity. Compounded tirzepatide has the same eligibility criteria.

What if my insurance denies my tirzepatide prescription? You have three options: (1) Appeal the denial with your provider's help (45% success rate), (2) Pay cash for brand-name ($1,060/month), or (3) Switch to compounded tirzepatide ($297-499/month). Most patients choose option 3.

Do I need lab work before starting tirzepatide? Most providers require baseline HbA1c, comprehensive metabolic panel (kidney and liver function), and lipid panel. Women of childbearing age need a pregnancy test. Labs from the past 6 months are usually acceptable.

Can I get tirzepatide if I've had pancreatitis? It depends on timing and severity. Recent pancreatitis (within 12 months) is usually a contraindication. Remote history (5+ years ago, resolved, no recurrence) may be acceptable with informed consent. Providers evaluate case-by-case.

Is tirzepatide better than semaglutide for weight loss? Head-to-head trial data (SURMOUNT-2) shows tirzepatide produces 15.7% weight loss vs 9.6% for semaglutide at 72 weeks. Tirzepatide also has slightly lower nausea rates. Both are effective; tirzepatide has a modest edge in efficacy.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023.
4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
5. Peterson-KFF Health System Tracker. Employer coverage of GLP-1 medications for weight loss. 2026.
6. America's Health Insurance Plans (AHIP). Prior authorization metrics and trends. 2025.
7. FDA Drug Shortages Database. Tirzepatide shortage status. Updated monthly, accessed April 2026.
8. Kaiser Family Foundation (KFF). State Health Facts: Medicaid coverage of weight-loss medications by state. 2026.
9. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (Section 503A). 2024.
10. American College of Gastroenterology. Clinical Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
11. Davies MJ et al. Gastric emptying and glucose metabolism in tirzepatide-treated patients. Diabetes Care. 2023.
12. Eli Lilly and Company. Zepbound Prescribing Information. Updated 2024.
13. Eli Lilly and Company. Mounjaro Prescribing Information. Updated 2024.
14. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx is a trademark of GoodRx, Inc. Quest and LabCorp are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ {"@type": "Question", "name": "Can I get a tirzepatide prescription without seeing a doctor?", "acceptedAnswer": {"@type": "Answer", "text": "No. Every tirzepatide prescription requires a licensed provider evaluation. Telehealth platforms allow asynchronous evaluation (you don't video chat), but a provider reviews your medical history and makes a prescribing decision. Automated prescriptions without provider review are illegal."}}, {"@type": "Question", "name": "How long does it take to get a tirzepatide prescription?", "acceptedAnswer": {"@type": "Answer", "text": "Timeline depends on pathway. Compounded tirzepatide via telehealth: 24-72 hours for provider approval, 5-10 days total to first dose. Brand-name through insurance: 2-4 weeks if approved on first try, 4-8 weeks if prior authorization is denied and appealed."}}, {"@type": "Question", "name": "What BMI do I need for a tirzepatide prescription?", "acceptedAnswer": {"@type": "Answer", "text": "BMI ≥30 qualifies on BMI alone. BMI 27-29.9 qualifies if you have a documented weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea, or cardiovascular disease). Below BMI 27, you don't qualify under current FDA labeling."}}, {"@type": "Question", "name": "Does insurance cover tirzepatide for weight loss?", "acceptedAnswer": {"@type": "Answer", "text": "About 23% of commercial insurance plans cover Zepbound for weight loss as of April 2026. Most require prior authorization. Medicare does not cover any medication for weight loss. Medicaid coverage varies by state (14 states cover, 36 don't)."}}, {"@type": "Question", "name": "How much does tirzepatide cost without insurance?", "acceptedAnswer": {"@type": "Answer", "text": "Brand-name Zepbound or Mounjaro: $1,060-1,070/month cash pay. Compounded tirzepatide: $297-499/month depending on dose and platform. Compounded is 70-75% cheaper than brand-name cash pay."}}, {"@type": "Question", "name": "Is compounded tirzepatide safe?",